← All trials
NCT03647384
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2018
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 348
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Capital Medical UniversityCollaborator
- China Academy of Chinese Medical SciencesCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Shanghai UniversityCollaborator
- Henan Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Peking UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Beijing Xuanwu Traditional Chinese Medicine HospitalCollaborator
- Chinese Academy of Medical SciencesStudy chair
- Shaanxi University of Chinese MedicineCollaborator
- Shandong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.